News Article
Francis Medical Featured in BioWorld MedTech
December 17, 2018
Francis Medical, Inc. has been featured in BioWorld MedTech, a leading news source of advances in medical technology.
Recent Posts
Francis Medical Receives FDA 510(k) Clearance for Use of the Vanquish® Water Vapor System for Prostate Tissue Ablation in Patients with Intermediate Risk Prostate Cancer
MINNEAPOLIS (Dec. 2, 2025) – Francis Medical, Inc.,a privately-held medical device company developing the breakthrough Vanquish® Water Vapor Ablation System
Press Release: Francis Medical Announces Completion of Enrollment in the VAPOR 2 Pivotal Study for Vanquish Prostate Cancer Treatment
February 25, 2025: Francis Medical completes enrollment in the company's VAPOR 2 Pivotal Study for Vanquish Prostate Cancer Treatment
Press Release: Francis Medical Announces Close of Record $80 Million Series C Equity Financing
January 8, 2025: Francis Medical raises record $80M in Series C to fund its VAPOR 2 study and U.S. launch of Vanquish, its proprietary prostate cancer treatment
Federal law (USA) restricts this device to sale by or on the order of a physician.
Refer to the device User Manual for a list of contraindications, warnings, and cautions.
Training: Do not operate the Vanquish System without completing Francis Medical-provided physician training. Untrained operation of the device may lead to improper use. Improper use can result in patient injury or equipment malfunction.